Biotech article - November 11, 2026
Circio and Solid Biosciences test circular RNA in heart gene therapy
Circio has started a research collaboration with US company Solid Biosciences to evaluate whether combining its circVec circular RNA technology with Solid's AAV capsid, POLARIS-101, can produce more potent and targeted gene therapies for genetic heart disease.
Biotech Business - November 3, 2026
Vitroscope raises USD 7 million to scale up live-tissue platform
Trondheim-based Vitroscope has raised USD 7 million, made up of a USD 5 million seed round co-led by Cerberus Ventures and YZR Capital and USD 2 million in non-dilutive funding from the Research Council of Norway.
Biotech Business - November 2, 2026
BioInvent plans SEK 430 million rights issue
Swedish biotech BioInvent plans a rights issue of approximately SEK 430 million to fund development of its anti-TNFR2 antibody BI-1808 and its other priority programs. The company also proposes to cut up to 20 positions.
Acquisition - October 31, 2026
Alligator sells mitazalimab to Biossil
Lund-based Alligator Bioscience has agreed to sell all rights and assets related to its CD40 agonist antibody mitazalimab to Biossil. The deal includes an upfront payment of USD 0.75 million, milestone payments of up to USD 108 million, and royalties on future sales.
Biotech Business - October 27, 2026
FDA approves Xbrane’s Lucentis biosimilar
The US Food and Drug Administration has approved Xbrane Biopharma’s Lucamzi (ranibizumab-blrz) as a biosimilar to Lucentis. The approval gives US patients a lower-cost option for treating wet age-related macular degeneration (AMD) and other serious eye conditions.
Biotech Business - October 20, 2026
FDA approves Alvotech’s new SIMLANDI process
The US Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI, Alvotech’s biosimilar to Humira, that more than doubles drug substance output per batch at the company’s facility in Reykjavik.